- Title
- Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A
- Creators
- Susana Banerjee - Royal Marsden NHS Foundation TrustEls Van Nieuwenhuysen - Universitaire Ziekenhuizen Leuven, Leuven, BelgiumAlessandro Santin - Yale School of MedicineKari Ring - University of VirginiaNicoletta Colombo - University of MilanPremal Thaker - Washington University in St. LouisEmily Prendergast - Minnesota OncologyAndrew Clamp - University of ManchesterIsabelle Ray-Coquard - Centre Léon BérardHye Sook Chon - Moffitt Cancer CenterKathleen Moore - University of Oklahoma Health Sciences CenterErin Salinas - Compass OncologyPeter Rose - Cleveland ClinicDavid O'Malley - The Ohio State UniversityAna Oaknin - Vall d'Hebron Hospital UniversitariBradley Monk - University of ArizonaRobert Holloway - Advent Health Cancer Institute, Orlando, FL, United StatesGregg Newman - Sansum Clinic, US Oncology, Santa Barbara, CA, United StatesJohn Moroney - University of ChicagoToon Van Gorp - Universitaire Ziekenhuizen Leuven, Leuven, BelgiumElsa Kalbacher - Hospital Jean Minjoz, Clermont-Ferrand, FranceChristine Gennigens - Centre Hospitalier Universitaire de LiègeNicholas Wojtynek - VerastemStephanie Lustgarten - VerastemRachel Grisham - Memorial Sloan Kettering Cancer Center
- Publication Details
- Gynecologic oncology, Vol.190, pp.S55-S56
- Publisher
- Elsevier Inc
- Identifiers
- 991006118537502656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A
Gynecologic oncology, Vol.190, pp.S55-S56
11/2024
Metrics
1 Record Views